Tags

Type your tag names separated by a space and hit enter

CGRP antagonists: unravelling the role of CGRP in migraine.
Trends Pharmacol Sci 2007; 28(11):580-7TP

Abstract

Migraine is a complex, debilitating neurovascular disorder. Although knowledge on the main molecular players is still incomplete, recent preclinical and clinical findings indicate that there is a clear correlation between migraine-associated headache and the release of the neuropeptide calcitonin gene-related peptide (CGRP). BIBN4096 was the first CGRP antagonist to be tested in clinical trials for the treatment of migraine. The proven efficacy of this agent, and also the CGRP antagonist MK-0974, to alleviate acute migraine headache provided significant support for the hypothesis that CGRP has an important role in migraine pathophysiology. Moreover, the recently published results from Phase II trials are encouraging and suggest that this new type of drug might offer advantages over existing therapies for patients suffering from migraine and related headaches.

Authors+Show Affiliations

Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany. henri.doods@boehringer-ingelheim.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17963849

Citation

Doods, Henri, et al. "CGRP Antagonists: Unravelling the Role of CGRP in Migraine." Trends in Pharmacological Sciences, vol. 28, no. 11, 2007, pp. 580-7.
Doods H, Arndt K, Rudolf K, et al. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007;28(11):580-7.
Doods, H., Arndt, K., Rudolf, K., & Just, S. (2007). CGRP antagonists: unravelling the role of CGRP in migraine. Trends in Pharmacological Sciences, 28(11), pp. 580-7.
Doods H, et al. CGRP Antagonists: Unravelling the Role of CGRP in Migraine. Trends Pharmacol Sci. 2007;28(11):580-7. PubMed PMID: 17963849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CGRP antagonists: unravelling the role of CGRP in migraine. AU - Doods,Henri, AU - Arndt,Kirsten, AU - Rudolf,Klaus, AU - Just,Stefan, Y1 - 2007/10/25/ PY - 2006/11/28/received PY - 2007/08/30/revised PY - 2007/10/12/accepted PY - 2007/10/30/pubmed PY - 2008/2/6/medline PY - 2007/10/30/entrez SP - 580 EP - 7 JF - Trends in pharmacological sciences JO - Trends Pharmacol. Sci. VL - 28 IS - 11 N2 - Migraine is a complex, debilitating neurovascular disorder. Although knowledge on the main molecular players is still incomplete, recent preclinical and clinical findings indicate that there is a clear correlation between migraine-associated headache and the release of the neuropeptide calcitonin gene-related peptide (CGRP). BIBN4096 was the first CGRP antagonist to be tested in clinical trials for the treatment of migraine. The proven efficacy of this agent, and also the CGRP antagonist MK-0974, to alleviate acute migraine headache provided significant support for the hypothesis that CGRP has an important role in migraine pathophysiology. Moreover, the recently published results from Phase II trials are encouraging and suggest that this new type of drug might offer advantages over existing therapies for patients suffering from migraine and related headaches. SN - 0165-6147 UR - https://www.unboundmedicine.com/medline/citation/17963849/CGRP_antagonists:_unravelling_the_role_of_CGRP_in_migraine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-6147(07)00230-1 DB - PRIME DP - Unbound Medicine ER -